Compare Stocks: PRTA, ZYME, KARD, and VCEL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KARD Kardigan	$18.52	$21.22	$16.25 ▼ $27.00	$1.73B	N/A	284,566 shs	416,399 shs
PRTA Prothena	$8.93	$9.02	$7.73 ▼ $11.80	$467.49M	-0.33	317,599 shs	376,273 shs
VCEL Vericel	$38.34	$44.03	$28.95 ▼ $49.32	$1.96B	1.04	460,253 shs	503,528 shs
ZYME Zymeworks	$26.24	$25.72	$15.49 ▼ $31.34	$1.86B	1.19	714,396 shs	1.03 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KARD Kardigan	0.00%	-11.18%	-8.32%	+1,851,999,900.00%	+1,851,999,900.00%
PRTA Prothena	0.00%	-9.06%	+0.79%	+9.57%	+8.77%
VCEL Vericel	0.00%	-4.60%	-13.26%	+0.13%	+19.14%
ZYME Zymeworks	0.00%	-10.11%	+4.46%	+12.81%	+66.71%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KARD Kardigan	$18.52	$21.22	$16.25 ▼ $27.00	$1.73B	N/A	284,566 shs	416,399 shs
PRTA Prothena	$8.93	$9.02	$7.73 ▼ $11.80	$467.49M	-0.33	317,599 shs	376,273 shs
VCEL Vericel	$38.34	$44.03	$28.95 ▼ $49.32	$1.96B	1.04	460,253 shs	503,528 shs
ZYME Zymeworks	$26.24	$25.72	$15.49 ▼ $31.34	$1.86B	1.19	714,396 shs	1.03 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KARD Kardigan	0.00%	-11.18%	-8.32%	+1,851,999,900.00%	+1,851,999,900.00%
PRTA Prothena	0.00%	-9.06%	+0.79%	+9.57%	+8.77%
VCEL Vericel	0.00%	-4.60%	-13.26%	+0.13%	+19.14%
ZYME Zymeworks	0.00%	-10.11%	+4.46%	+12.81%	+66.71%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
KARD Kardigan	2.80	Moderate Buy	$42.25	128.13% Upside
PRTA Prothena	2.75	Moderate Buy	$24.57	175.16% Upside
VCEL Vericel	2.57	Moderate Buy	$58.40	52.32% Upside
ZYME Zymeworks	2.73	Moderate Buy	$41.00	56.25% Upside

Current Analyst Ratings Breakdown

Latest PRTA, ZYME, KARD, and VCEL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/9/2026	PRTA Prothena	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/3/2026	ZYME Zymeworks	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$31.00 ➝ $33.00
8/26/2026	ZYME Zymeworks	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$32.00
8/26/2026	ZYME Zymeworks	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/26/2026	ZYME Zymeworks	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$37.00 ➝ $38.00
8/26/2026	ZYME Zymeworks	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform	$32.00
8/26/2026	ZYME Zymeworks	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$51.00 ➝ $55.00
8/25/2026	KARD Kardigan	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$51.00 ➝ $46.00
8/11/2026	PRTA Prothena	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/10/2026	ZYME Zymeworks	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$40.00 ➝ $44.00
8/10/2026	ZYME Zymeworks	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy

(Data available from 9/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
KARD Kardigan	N/A	N/A	N/A	N/A	N/A	N/A
PRTA Prothena	$9.68M	48.29	N/A	N/A	$5.21 per share	1.71
VCEL Vericel	$276.26M	7.11	$0.56 per share	69.02	$7.01 per share	5.47
ZYME Zymeworks	$105.96M	17.57	N/A	N/A	$3.59 per share	7.31

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
KARD Kardigan	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PRTA Prothena	-$244.09M	-$0.84	N/A	N/A	3.15	-80.68%	-16.45%	-14.51%	11/5/2026 (Estimated)
VCEL Vericel	$16.52M	$0.47	81.58	45.64	N/A	7.91%	6.91%	5.02%	11/5/2026 (Estimated)
ZYME Zymeworks	-$81.13M	-$2.02	N/A	51.45	N/A	-405.31%	-72.30%	-37.18%	11/5/2026 (Estimated)

Latest PRTA, ZYME, KARD, and VCEL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	KARD Kardigan	N/A	-$4.61	N/A	-$4.61	N/A	N/A
8/7/2026	Q2 2026	ZYME Zymeworks	-$0.5620	-$0.62	-$0.0580	-$0.62	$4.54 million	$3.23 million
8/6/2026	Q2 2026	PRTA Prothena	-$0.39	-$0.32	+$0.07	-$0.36	$0.42 million	$1.01 million
7/30/2026	Q2 2026	VCEL Vericel	-$0.0289	$0.04	+$0.0689	$0.04	$72.70 million	$77.46 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
KARD Kardigan	N/A	N/A	N/A	N/A	N/A
PRTA Prothena	N/A	N/A	N/A	N/A	N/A
VCEL Vericel	N/A	N/A	N/A	N/A	N/A
ZYME Zymeworks	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
KARD Kardigan	N/A	N/A	N/A
PRTA Prothena	N/A	25.05	25.05
VCEL Vericel	N/A	5.04	4.69
ZYME Zymeworks	N/A	6.32	6.32

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
KARD Kardigan	N/A
PRTA Prothena	97.08%
VCEL Vericel	N/A
ZYME Zymeworks	92.89%

Insider Ownership

Company	Insider Ownership
KARD Kardigan	N/A
PRTA Prothena	10.40%
VCEL Vericel	7.60%
ZYME Zymeworks	33.51%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
KARD Kardigan	241	93.50 million	N/A	N/A
PRTA Prothena	67	52.35 million	46.91 million	Optionable
VCEL Vericel	398	51.21 million	47.32 million	Optionable
ZYME Zymeworks	264	70.96 million	47.18 million	N/A

PRTA, ZYME, KARD, and VCEL Headlines

Recent News About These Companies

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 238,026 Shares of Zymeworks Inc. $ZYME

September 12 at 4:31 AM | marketbeat.com

Wellington Management Group LLP Takes $2.88 Million Position in Zymeworks Inc. $ZYME

September 11 at 4:47 AM | marketbeat.com

Legal & General Group Plc Makes New $1.13 Million Investment in Zymeworks Inc. $ZYME

September 8, 2026 | marketbeat.com

Bank of New York Mellon Corp Acquires New Holdings in Zymeworks Inc. $ZYME

September 7, 2026 | marketbeat.com

Zymeworks (NASDAQ:ZYME) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

September 5, 2026 | americanbankingnews.com

Zymeworks (NASDAQ:ZYME) Hits New 52-Week High - Still a Buy?

September 4, 2026 | americanbankingnews.com

Zymeworks stock gains analyst support after FDA cancer therapy approval

September 4, 2026 | ad-hoc-news.deA

JPMorgan Chase & Co. Boosts Zymeworks (NASDAQ:ZYME) Price Target to $33.00

September 3, 2026 | marketbeat.com

Zymeworks (NASDAQ:ZYME) Hits New 1-Year High - Time to Buy?

September 2, 2026 | marketbeat.com

Man Group plc Invests $5.51 Million in Zymeworks Inc. $ZYME

August 30, 2026 | marketbeat.com

4,251,030 Shares in Zymeworks Inc. $ZYME Bought by BlackRock Inc.

August 30, 2026 | marketbeat.com

Zymeworks stock holds near $28.27 as market cap tops $2.01 billion

August 29, 2026 | ad-hoc-news.deA

Zymeworks (ZYME), What Is Behind The Renewed Attention?

August 28, 2026 | finance.yahoo.com

FY2026 EPS Estimates for Zymeworks Raised by HC Wainwright

August 28, 2026 | marketbeat.com

Zymeworks Inc.: U.S. FDA Approves Ziihera (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma

August 27, 2026 | finanznachrichten.de

Zymeworks: Transitioning Into A Royalty-Driven Biopharma Platform Post Ziihera Approval

August 27, 2026 | seekingalpha.com

HC Wainwright Has Strong Estimate for Zymeworks Q3 Earnings

August 27, 2026 | marketbeat.com

Bank of America Corp DE Raises Position in Zymeworks Inc. $ZYME

August 27, 2026 | marketbeat.com

SJM, ZYME stocks hit 52-week high – what’s driving the surge today?

August 26, 2026 | msn.com

JAZZ Secures FDA Nod for Expanded Use of Ziihera in Gastric Cancer

August 26, 2026 | zacks.com

Zymeworks (NASDAQ:ZYME) Price Target Raised to $38.00 at Citigroup

August 26, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

PRTA, ZYME, KARD, and VCEL Company Descriptions

Kardigan NASDAQ:KARD

$18.52 0.00 (0.00%)

As of 09/11/2026 04:00 PM Eastern

Kardigan Inc. is a clinical-stage precision therapeutics company developing medicines which target the root cause of specific cardiovascular diseases. Kardigan Inc. is based in South San Francisco, California.

Prothena NASDAQ:PRTA

$8.93 0.00 (0.00%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$8.93 0.00 (-0.06%)

As of 09/11/2026 07:30 PM Eastern

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.

Vericel NASDAQ:VCEL

$38.34 0.00 (0.00%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$38.34 0.00 (0.00%)

As of 09/11/2026 07:30 PM Eastern

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

Zymeworks NASDAQ:ZYME

$26.24 0.00 (0.00%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$26.26 +0.03 (+0.10%)

As of 09/11/2026 07:30 PM Eastern

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PRTA, ZYME, KARD, and VCEL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PRTA, ZYME, KARD, and VCEL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PRTA, ZYME, KARD, and VCEL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PRTA, ZYME, KARD, and VCEL Company Descriptions

Kardigan NASDAQ:KARD

Prothena NASDAQ:PRTA

Vericel NASDAQ:VCEL

Zymeworks NASDAQ:ZYME

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PRTA, ZYME, KARD, and VCEL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PRTA, ZYME, KARD, and VCEL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PRTA, ZYME, KARD, and VCEL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PRTA, ZYME, KARD, and VCEL Company Descriptions

Kardigan NASDAQ:KARD

Prothena NASDAQ:PRTA

Vericel NASDAQ:VCEL

Zymeworks NASDAQ:ZYME

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools